We provide you with 20 years of free, institutional-grade data for AKTX stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of AKTX. Explore the full financial landscape of AKTX stock.
| Reported Date | CIK | Ticker | Type |
|---|
Akari Therapeutics, Plc(NASDAQ:AKTX) 
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases. Its lead product candidate is Coversin, a second-generation complement inhibitor that is in Phase I...
The information provided in this report about AKTX stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.